HCC
MCID: HPT023
MIFTS: 97

Hepatocellular Carcinoma (HCC)

Categories: Cancer diseases, Endocrine diseases, Gastrointestinal diseases, Genetic diseases, Liver diseases, Rare diseases

Aliases & Classifications for Hepatocellular Carcinoma

MalaCards integrated aliases for Hepatocellular Carcinoma:

Name: Hepatocellular Carcinoma 58 39 12 77 76 38 30 13 56 6 15 17
Liver Cancer 58 12 76 44 15
Hepatoma 58 12 76 15
Primary Liver Cancer 12 54 15
Liver Neoplasms 77 45 74
Hcc 58 12 76
Adult Primary Hepatocellular Carcinoma 12 74
Primary Malignant Neoplasm of Liver 12 74
Malignant Neoplasm of Liver 12 74
Hepatoblastoma, Somatic 58 13
Cancer, Hepatocellular 58 41
Neoplasm of the Liver 30 6
Liver Cell Carcinoma 58 76
Hepatic Cancer 12 56
Hepatoblastoma 60 74
Lcc 58 76
Malignant Neoplasm of Liver, Not Specified As Primary or Secondary 12
Rare Tumor of Liver and Intrahepatic Biliary Tract 54
Hepatocellular Carcinoma, Childhood Type, Somatic 58
Non-Resectable Primary Hepatic Malignant Neoplasm 12
Liver and Intrahepatic Biliary Tract Carcinoma 74
Resectable Malignant Neoplasm of the Liver 12
Resectable Malignant Neoplasm of Liver 12
Malignant Neoplasm of Liver, Primary 12
Hepatocellular Carcinoma, Somatic 58
Malignant Hepato-Biliary Neoplasm 12
Primary Malignant Liver Neoplasm 54
Malignant Hepatobiliary Neoplasm 74
Hepatocellular Cancer, Somatic 58
Primary Tumor of the Liver 54
Liver Cell Carcinoma; Lcc 58
Carcinoma, Hepatocellular 45
Malignant Tumor of Liver 12
Primary Cancer of Liver 54
Primary Liver Carcinoma 54
Hepatocellular Cancer 76
Ca Liver - Primary 12
Neoplasm of Liver 12
Hepatic Neoplasm 12
Liver Carcinoma 74
Adult Hepatoma 12
Liver Neoplasm 17

Characteristics:

Orphanet epidemiological data:

60
hepatoblastoma
Inheritance: Not applicable; Prevalence: <1/1000000 (Europe),1-9/1000000 (Europe); Age of onset: Childhood,Infancy,Neonatal; Age of death: early childhood,infantile;

OMIM:

58
Inheritance:
somatic mutation

Miscellaneous:
genetic heterogeneity


HPO:

33
hepatocellular carcinoma:
Inheritance somatic mutation heterogeneous autosomal dominant inheritance


Classifications:

Orphanet: 60  
Rare hepatic diseases


Summaries for Hepatocellular Carcinoma

MedlinePlus : 44 Your liver is the largest organ inside your body. It helps your body digest food, store energy, and remove poisons. Primary liver cancer starts in the liver. Metastatic liver cancer starts somewhere else and spreads to your liver. Risk factors for primary liver cancer include Having hepatitis B or C Heavy alcohol use Having cirrhosis, or scarring of the liver Having hemochromatosis, an iron storage disease Obesity and diabetes Symptoms can include a lump or pain on the right side of your abdomen and yellowing of the skin. However, you may not have symptoms until the cancer is advanced. This makes it harder to treat. Doctors use tests that examine the liver and the blood to diagnose liver cancer. Treatment options include surgery, radiation, chemotherapy, or liver transplantation. NIH: National Cancer Institute

MalaCards based summary : Hepatocellular Carcinoma, also known as liver cancer, is related to adult hepatocellular carcinoma and childhood hepatocellular carcinoma, and has symptoms including nausea and vomiting, constipation and fever. An important gene associated with Hepatocellular Carcinoma is PIK3CA (Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Alpha), and among its related pathways/superpathways are Hepatocellular carcinoma and Viral carcinogenesis. The drugs Sorafenib and Peginterferon alfa-2a have been mentioned in the context of this disorder. Affiliated tissues include liver, t cells and lung, and related phenotypes are hepatomegaly and portal hypertension

Disease Ontology : 12 A liver carcinoma that has material basis in undifferentiated hepatocytes.

OMIM : 58 Hepatocellular carcinoma is the major histologic type of malignant primary liver neoplasm. It is the fifth most common cancer and the third most common cause of death from cancer worldwide. The major risk factors for HCC are chronic hepatitis B virus (HBV) infection, chronic hepatitis C virus (HCV) infection, prolonged dietary aflatoxin exposure, alcoholic cirrhosis, and cirrhosis due to other causes. Hepatoblastomas comprise 1 to 2% of all malignant neoplasms of childhood, most often occurring in children under 3 years of age. Hepatoblastomas are thought to be derived from undifferentiated hepatocytes (Taniguchi et al., 2002). (114550)

UniProtKB/Swiss-Prot : 76 Hepatocellular carcinoma: A primary malignant neoplasm of epithelial liver cells. The major risk factors for HCC are chronic hepatitis B virus (HBV) infection, chronic hepatitis C virus (HCV) infection, prolonged dietary aflatoxin exposure, alcoholic cirrhosis, and cirrhosis due to other causes.

Wikipedia : 77 Hepatocellular carcinoma (HCC) is the most common type of primary liver cancer in adults, and is the... more...

Related Diseases for Hepatocellular Carcinoma

Diseases in the Hepatocellular Carcinoma family:

Adult Hepatocellular Carcinoma

Diseases related to Hepatocellular Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 865)
# Related Disease Score Top Affiliating Genes
1 adult hepatocellular carcinoma 35.2 AXIN1 CASP8 CTNNB1 PDGFRL PIK3CA TP53
2 childhood hepatocellular carcinoma 35.1 MET CTNNB1
3 cholangiocarcinoma 33.4 AKT1 CTNNB1 IDH1 IDH2 KRAS MET
4 colorectal cancer 32.8 AKT1 APC AXIN1 CASP8 CTNNB1 HRAS
5 breast cancer 32.7 AKT1 APC CASP8 CTNNB1 FGFR1 HRAS
6 intrahepatic cholangiocarcinoma 32.7 CTNNB1 IDH1 IDH2 KRAS TP53
7 adenocarcinoma 32.7 AKT1 APC CTNNB1 FGFR1 HRAS KRAS
8 gastric cancer 32.3 AKT1 APC CTNNB1 KRAS MET MIR122
9 lung cancer susceptibility 3 32.3 TP53 TERT PIK3CA NRAS NFE2L2 MET
10 adenoma 32.2 TP53 KRAS CTNNB1 APC
11 lung cancer 32.2 AKT1 CASP8 FGFR1 HRAS KRAS MET
12 esophageal cancer 32.2 AKT1 CASP8 CTNNB1 HRAS KRAS MIR21
13 prostate cancer 32.0 TP53 TERT PIK3CA MIR21 MET KRAS
14 squamous cell carcinoma 32.0 TP53 PIK3CA HRAS CTNNB1 AKT1
15 gastric adenocarcinoma 31.9 AKT1 APC CASP8 CTNNB1 FGFR1 HRAS
16 pancreas adenocarcinoma 31.9 AKT1 CTNNB1 HRAS KRAS MET PIK3CA
17 thyroid cancer 31.9 AKT1 APC CTNNB1 HRAS KRAS MET
18 hepatoblastoma 31.9 TP53 CTNNB1 APC
19 glioblastoma 31.8 AKT1 FGFR1 HRAS IDH1 IDH2 MET
20 pancreatic cancer 31.8 AKT1 CTNNB1 HRAS KRAS MET MIR21
21 cervical cancer 31.8 AKT1 CASP8 CTNNB1 HRAS MIR21 NFE2L2
22 glioma 31.7 TP53 PIK3CA MIR21 MET IDH2 IDH1
23 sarcoma 31.7 CTNNB1 HRAS KRAS PIK3CA TP53
24 myeloma, multiple 31.6 AKT1 CASP8 HRAS IDH1 IDH2 KRAS
25 familial adenomatous polyposis 31.6 APC AXIN1 CTNNB1 KRAS TP53
26 leukemia, acute myeloid 31.6 AKT1 CASP8 HRAS IDH1 IDH2 KRAS
27 ovarian cancer 31.6 AKT1 CASP8 CTNNB1 KRAS MIR21 PIK3CA
28 carcinosarcoma 31.6 TP53 PIK3CA KRAS HRAS CTNNB1
29 gallbladder cancer 31.5 AKT1 KRAS PIK3CA TERT TP53
30 adrenocortical carcinoma, hereditary 31.4 TP53 PIK3CA NRAS CTNNB1
31 adenoid cystic carcinoma 31.3 AKT1 CTNNB1 HRAS IDH1 KRAS PIK3CA
32 neuroblastoma 31.3 AKT1 CASP8 CTNNB1 FGFR1 NRAS PIK3CA
33 colon adenocarcinoma 31.3 KRAS CTNNB1 CASP8 APC
34 myelodysplastic syndrome 31.3 HRAS IDH1 IDH2 KRAS NRAS TERT
35 lymphoma, non-hodgkin, familial 31.3 CASP8 NRAS PIK3CA TP53
36 liver angiosarcoma 31.3 HRAS KRAS NRAS TP53
37 nasopharyngeal carcinoma 31.2 AKT1 HRAS NRAS PIK3CA TERT TP53
38 small cell cancer of the lung 31.2 TP53 PIK3CA MIR21 AKT1
39 gastrointestinal system disease 31.1 AKT1 CTNNB1 HRAS KRAS TP53
40 breast adenocarcinoma 31.1 AKT1 CASP8 KRAS PIK3CA TP53
41 bladder cancer 31.1 TP53 TERT MIR21 KRAS HRAS
42 cystadenocarcinoma 31.1 AKT1 HRAS PIK3CA TP53
43 adenosquamous carcinoma 31.0 KRAS PIK3CA TP53
44 ovary adenocarcinoma 31.0 HRAS KRAS PIK3CA TP53
45 glioblastoma multiforme 31.0 AKT1 IDH1 MET MIR21 PIK3CA TP53
46 colorectal adenocarcinoma 31.0 CTNNB1 HRAS KRAS TP53
47 lynch syndrome 31.0 TP53 KRAS CTNNB1 APC
48 kidney cancer 31.0 MET MIR122 MIR21 TP53
49 myeloid leukemia 30.9 HRAS IDH1 NRAS TP53
50 tongue squamous cell carcinoma 30.9 AKT1 CTNNB1 MIR21 TP53

Comorbidity relations with Hepatocellular Carcinoma via Phenotypic Disease Network (PDN):


Active Peptic Ulcer Disease Acute Cystitis
Alcoholic Liver Cirrhosis Deficiency Anemia
Hepatic Encephalopathy Intrahepatic Gall Duct Cancer
Portal Hypertension Protein-Energy Malnutrition

Graphical network of the top 20 diseases related to Hepatocellular Carcinoma:



Diseases related to Hepatocellular Carcinoma

Symptoms & Phenotypes for Hepatocellular Carcinoma

Human phenotypes related to Hepatocellular Carcinoma:

33 (show all 45)
# Description HPO Frequency HPO Source Accession
1 hepatomegaly 33 hallmark (90%) HP:0002240
2 portal hypertension 33 hallmark (90%) HP:0001409
3 abdominal pain 33 hallmark (90%) HP:0002027
4 hyperbilirubinemia 33 hallmark (90%) HP:0002904
5 hypoalbuminemia 33 hallmark (90%) HP:0003073
6 type ii diabetes mellitus 33 frequent (33%) HP:0005978
7 weight loss 33 frequent (33%) HP:0001824
8 anorexia 33 frequent (33%) HP:0002039
9 esophageal varix 33 frequent (33%) HP:0002040
10 venous insufficiency 33 frequent (33%) HP:0005293
11 abdominal distention 33 frequent (33%) HP:0003270
12 abnormality of the rectum 33 frequent (33%) HP:0002034
13 epigastric pain 33 frequent (33%) HP:0410019
14 elevated hepatic transaminase 33 frequent (33%) HP:0002910
15 fever 33 occasional (7.5%) HP:0001945
16 hypokalemia 33 occasional (7.5%) HP:0002900
17 fatigue 33 occasional (7.5%) HP:0012378
18 dyspnea 33 occasional (7.5%) HP:0002094
19 hypoglycemia 33 occasional (7.5%) HP:0001943
20 ascites 33 occasional (7.5%) HP:0001541
21 anemia 33 occasional (7.5%) HP:0001903
22 neoplasm 33 occasional (7.5%) HP:0002664
23 thrombocytopenia 33 occasional (7.5%) HP:0001873
24 jaundice 33 occasional (7.5%) HP:0000952
25 thrombocytosis 33 occasional (7.5%) HP:0001894
26 hyponatremia 33 occasional (7.5%) HP:0002902
27 hypercalcemia 33 occasional (7.5%) HP:0003072
28 diarrhea 33 occasional (7.5%) HP:0002014
29 bone pain 33 occasional (7.5%) HP:0002653
30 internal hemorrhage 33 occasional (7.5%) HP:0011029
31 polycythemia 33 occasional (7.5%) HP:0001901
32 poor appetite 33 occasional (7.5%) HP:0004396
33 metabolic alkalosis 33 occasional (7.5%) HP:0200114
34 mood changes 33 occasional (7.5%) HP:0001575
35 hepatic encephalopathy 33 occasional (7.5%) HP:0002480
36 hepatic necrosis 33 occasional (7.5%) HP:0002605
37 anasarca 33 occasional (7.5%) HP:0012050
38 pedal edema 33 occasional (7.5%) HP:0010741
39 hemobilia 33 occasional (7.5%) HP:0100762
40 hypotension 33 very rare (1%) HP:0002615
41 liver abscess 33 very rare (1%) HP:0100523
42 budd-chiari syndrome 33 very rare (1%) HP:0002639
43 hepatocellular carcinoma 33 HP:0001402
44 micronodular cirrhosis 33 HP:0001413
45 subacute progressive viral hepatitis 33 HP:0006572

Symptoms via clinical synopsis from OMIM:

58
Abdomen Liver:
hepatocellular carcinoma
micronodular cirrhosis
subacute progressive viral hepatitis

Laboratory Abnormalities:
often integrated hbv sequences in hepatocellular carcinomas

Neoplasia:
primary liver cancer

Clinical features from OMIM:

114550

UMLS symptoms related to Hepatocellular Carcinoma:


nausea and vomiting, constipation, fever, abdominal pain, diarrhea, hepatosplenomegaly, icterus, dyspepsia, heartburn, gastrointestinal gas, malaise

GenomeRNAi Phenotypes related to Hepatocellular Carcinoma according to GeneCards Suite gene sharing:

27 (show all 49)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-2 10.6 HRAS KRAS PIK3CA
2 Decreased viability GR00106-A-0 10.6 KRAS
3 Decreased viability GR00221-A-1 10.6 AKT1 FGFR1 HRAS KRAS PIK3CA NRAS
4 Decreased viability GR00221-A-2 10.6 AKT1 FGFR1 HRAS KRAS PIK3CA
5 Decreased viability GR00221-A-3 10.6 AKT1 HRAS NRAS
6 Decreased viability GR00221-A-4 10.6 AKT1 PIK3CA
7 Decreased viability GR00301-A 10.6 KRAS
8 Decreased viability GR00381-A-1 10.6 KRAS
9 Decreased viability GR00402-S-2 10.6 AKT1 FGFR1 HRAS KRAS PIK3CA NRAS
10 Increased shRNA abundance (Z-score > 2) GR00366-A-103 10.29 IGF2R
11 Increased shRNA abundance (Z-score > 2) GR00366-A-105 10.29 IGF2R
12 Increased shRNA abundance (Z-score > 2) GR00366-A-11 10.29 CTNNB1 KRAS
13 Increased shRNA abundance (Z-score > 2) GR00366-A-113 10.29 CTNNB1
14 Increased shRNA abundance (Z-score > 2) GR00366-A-116 10.29 PIK3CA
15 Increased shRNA abundance (Z-score > 2) GR00366-A-120 10.29 KRAS
16 Increased shRNA abundance (Z-score > 2) GR00366-A-133 10.29 APC
17 Increased shRNA abundance (Z-score > 2) GR00366-A-146 10.29 IGF2R
18 Increased shRNA abundance (Z-score > 2) GR00366-A-157 10.29 PIK3CA
19 Increased shRNA abundance (Z-score > 2) GR00366-A-16 10.29 PIK3CA AKT1 IDH2
20 Increased shRNA abundance (Z-score > 2) GR00366-A-166 10.29 PIK3CA
21 Increased shRNA abundance (Z-score > 2) GR00366-A-168 10.29 KRAS
22 Increased shRNA abundance (Z-score > 2) GR00366-A-176 10.29 IDH2
23 Increased shRNA abundance (Z-score > 2) GR00366-A-177 10.29 APC CTNNB1 KRAS PIK3CA AKT1 IDH2
24 Increased shRNA abundance (Z-score > 2) GR00366-A-190 10.29 PIK3CA
25 Increased shRNA abundance (Z-score > 2) GR00366-A-192 10.29 APC
26 Increased shRNA abundance (Z-score > 2) GR00366-A-196 10.29 KRAS
27 Increased shRNA abundance (Z-score > 2) GR00366-A-197 10.29 CTNNB1
28 Increased shRNA abundance (Z-score > 2) GR00366-A-199 10.29 IDH2
29 Increased shRNA abundance (Z-score > 2) GR00366-A-202 10.29 APC
30 Increased shRNA abundance (Z-score > 2) GR00366-A-207 10.29 IGF2R
31 Increased shRNA abundance (Z-score > 2) GR00366-A-22 10.29 KRAS
32 Increased shRNA abundance (Z-score > 2) GR00366-A-23 10.29 KRAS
33 Increased shRNA abundance (Z-score > 2) GR00366-A-25 10.29 IGF2R
34 Increased shRNA abundance (Z-score > 2) GR00366-A-29 10.29 APC
35 Increased shRNA abundance (Z-score > 2) GR00366-A-42 10.29 PIK3CA AKT1 IDH2
36 Increased shRNA abundance (Z-score > 2) GR00366-A-47 10.29 CTNNB1
37 Increased shRNA abundance (Z-score > 2) GR00366-A-49 10.29 APC CTNNB1 IGF2R KRAS PIK3CA
38 Increased shRNA abundance (Z-score > 2) GR00366-A-50 10.29 KRAS AKT1
39 Increased shRNA abundance (Z-score > 2) GR00366-A-63 10.29 KRAS
40 Increased shRNA abundance (Z-score > 2) GR00366-A-67 10.29 CTNNB1
41 Increased shRNA abundance (Z-score > 2) GR00366-A-69 10.29 IDH2
42 Increased shRNA abundance (Z-score > 2) GR00366-A-70 10.29 AKT1
43 Increased shRNA abundance (Z-score > 2) GR00366-A-73 10.29 CTNNB1 IGF2R IDH2
44 Increased shRNA abundance (Z-score > 2) GR00366-A-74 10.29 APC CTNNB1
45 Increased shRNA abundance (Z-score > 2) GR00366-A-79 10.29 CTNNB1 AKT1
46 Increased shRNA abundance (Z-score > 2) GR00366-A-85 10.29 AKT1
47 Increased shRNA abundance (Z-score > 2) GR00366-A-93 10.29 KRAS
48 Decreased cell migration GR00055-A-1 9.73 AKT1 CTNNB1 HRAS KRAS MET PIK3CA
49 Increased cell migration GR00055-A-3 9.26 CTNNB1 HRAS KRAS PIK3CA

MGI Mouse Phenotypes related to Hepatocellular Carcinoma:

47 (show all 27)
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.5 AKT1 APC AXIN1 CASP8 CTNNB1 FGFR1
2 growth/size/body region MP:0005378 10.49 AKT1 APC AXIN1 CASP8 CTNNB1 FGFR1
3 cellular MP:0005384 10.47 AKT1 APC AXIN1 CASP8 CTNNB1 FGFR1
4 behavior/neurological MP:0005386 10.45 AKT1 APC AXIN1 CTNNB1 FGFR1 HRAS
5 homeostasis/metabolism MP:0005376 10.44 AKT1 APC CASP8 CTNNB1 FGFR1 HRAS
6 embryo MP:0005380 10.42 AKT1 APC AXIN1 CASP8 CTNNB1 FGFR1
7 endocrine/exocrine gland MP:0005379 10.41 AKT1 APC CASP8 CTNNB1 FGFR1 HRAS
8 mortality/aging MP:0010768 10.41 AKT1 APC AXIN1 CASP8 CTNNB1 FGFR1
9 immune system MP:0005387 10.37 AKT1 APC CASP8 CTNNB1 FGFR1 IDH1
10 craniofacial MP:0005382 10.36 APC AXIN1 CTNNB1 FGFR1 HRAS IGF2R
11 digestive/alimentary MP:0005381 10.35 APC AXIN1 CTNNB1 FGFR1 HRAS KRAS
12 hematopoietic system MP:0005397 10.35 AKT1 APC CASP8 CTNNB1 FGFR1 IDH1
13 nervous system MP:0003631 10.3 AKT1 APC AXIN1 CASP8 CTNNB1 FGFR1
14 integument MP:0010771 10.29 AKT1 APC CASP8 CTNNB1 FGFR1 HRAS
15 neoplasm MP:0002006 10.29 AKT1 APC CASP8 CTNNB1 HRAS IDH2
16 liver/biliary system MP:0005370 10.22 AKT1 APC CASP8 CTNNB1 IGF2R KRAS
17 normal MP:0002873 10.22 AKT1 APC AXIN1 CTNNB1 FGFR1 HRAS
18 limbs/digits/tail MP:0005371 10.19 APC AXIN1 CTNNB1 FGFR1 IGF2R KRAS
19 muscle MP:0005369 10.15 AKT1 APC CASP8 CTNNB1 FGFR1 KRAS
20 hearing/vestibular/ear MP:0005377 10.06 APC AXIN1 CTNNB1 FGFR1 KRAS TP53
21 renal/urinary system MP:0005367 10.06 APC AXIN1 CASP8 CTNNB1 FGFR1 HRAS
22 no phenotypic analysis MP:0003012 10.03 CTNNB1 FGFR1 HRAS KRAS MET NRAS
23 reproductive system MP:0005389 9.96 AKT1 APC AXIN1 CTNNB1 FGFR1 IGF2R
24 respiratory system MP:0005388 9.93 AKT1 AXIN1 CASP8 CTNNB1 HRAS IDH1
25 skeleton MP:0005390 9.8 AKT1 APC AXIN1 CTNNB1 FGFR1 HRAS
26 pigmentation MP:0001186 9.77 APC CTNNB1 KRAS NRAS TP53
27 vision/eye MP:0005391 9.23 APC CTNNB1 FGFR1 KRAS MET NRAS

Drugs & Therapeutics for Hepatocellular Carcinoma

Drugs for Hepatocellular Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 759)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Sorafenib Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 284461-73-0 216239 406563
2
Peginterferon alfa-2a Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 198153-51-4 5360545
3
Ribavirin Approved Phase 4,Phase 3,Phase 2,Early Phase 1,Not Applicable 36791-04-5 37542
4
Lamivudine Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 134678-17-4 60825
5
Entecavir Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 142217-69-4 153941
6 Ethiodized oil Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 8008-53-5
7
Carboplatin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 41575-94-4 38904 10339178 498142
8
Ethanol Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 64-17-5 702
9
Cefazolin Approved Phase 4 25953-19-9 656510 33255
10
acetic acid Approved Phase 4 64-19-7 176
11
Propranolol Approved, Investigational Phase 4,Phase 3,Phase 2,Early Phase 1,Not Applicable 525-66-6 4946
12
Telbivudine Approved, Investigational Phase 4,Phase 1,Phase 2 3424-98-4 159269
13
Oxaliplatin Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 61825-94-3 6857599 5310940 9887054 43805
14
Coal tar Approved Phase 4,Phase 3,Phase 2,Phase 1 8007-45-2
15
Iodine Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable,Early Phase 1 7553-56-2 807
16
Adefovir Dipivoxil Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 142340-99-6 60871
17
Sevoflurane Approved, Vet_approved Phase 4 28523-86-6 5206
18
Desflurane Approved Phase 4 57041-67-5 42113
19
Nadolol Approved Phase 4 42200-33-9 39147
20
Pravastatin Approved Phase 4,Phase 3,Phase 2 81093-37-0 54687
21
Ursodeoxycholic acid Approved, Investigational Phase 4,Phase 2 128-13-2 31401
22
Fluorouracil Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 51-21-8 3385
23
Tegafur Approved, Investigational Phase 4,Phase 2,Phase 1 17902-23-7 5386
24
Irinotecan Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 100286-90-6, 97682-44-5 60838
25
Levoleucovorin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 68538-85-2
26
leucovorin Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 58-05-9 6006 143
27
Cetuximab Approved Phase 4,Phase 2,Phase 1,Not Applicable,Early Phase 1 205923-56-4 56842117 2333
28
Raltitrexed Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 112887-68-0 104758
29
Tocopherol Approved, Investigational Phase 4,Phase 1,Phase 2 1406-66-2 14986
30
Epirubicin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 56420-45-2 41867
31
Capecitabine Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 154361-50-9 60953
32
Trastuzumab Approved, Investigational Phase 4,Phase 2,Phase 1 180288-69-1 9903
33
Bevacizumab Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 216974-75-3
34
Triamcinolone Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1 124-94-7 31307
35
Doxorubicin Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 23214-92-8 31703
36
Cisplatin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 15663-27-1 441203 84093 2767
37
Everolimus Approved Phase 4,Phase 3,Phase 2,Phase 1 159351-69-6 6442177 70789204
38
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 22916-47-8 4189
39
Sirolimus Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 53123-88-9 46835353 6436030 5284616
40
Tacrolimus Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 104987-11-3 445643 439492 6473866
41
Ritonavir Approved, Investigational Phase 4,Phase 3,Phase 2 155213-67-5 392622
42
Metformin Approved Phase 4,Phase 3,Phase 2,Phase 1 657-24-9 14219 4091
43
Peginterferon alfa-2b Approved Phase 4,Phase 3,Phase 2 99210-65-8, 215647-85-1
44
Aspirin Approved, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable 50-78-2 2244
45
Sargramostim Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 123774-72-1, 83869-56-1
46
Acetaminophen Approved Phase 4,Not Applicable 103-90-2 1983
47
Iron Approved, Experimental Phase 4,Phase 3,Phase 2,Phase 1 7439-89-6, 15438-31-0 23925 27284
48
Atorvastatin Approved Phase 4,Phase 2 134523-00-5 60823
49
Celecoxib Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2 169590-42-5 2662
50
carbamide peroxide Approved Phase 4,Phase 2 124-43-6

Interventional clinical trials:

(show top 50) (show all 2781)
# Name Status NCT ID Phase Drugs
1 Clinical Trial for GALNT14 Genotype - Guided, Sorafenib in Combination With TACE in Hepatocellular Carcinoma Unknown status NCT02504983 Phase 4 sorafenib
2 Transarterial Radioembolization Versus Chemoembolization for the Treatment of Hepatocellular Carcinoma Unknown status NCT02729506 Phase 4
3 Percutaneous Radiofrequency Ablation Versus Repeat Hepatectomy for Recurrent Hepatocellular Carcinoma Unknown status NCT01570166 Phase 4
4 Radiofrequency Ablation Versus Liver Resection for Elderly Patients With Hepatocellular Carcinoma (HCC) Within the Milan Criteria Unknown status NCT01570075 Phase 4
5 A Prospective Control Study of Cidan Capsule Combined With TACE in Hepatocellular Carcinoma Unknown status NCT02253511 Phase 4 Cidan capsule
6 Peginterferon Plus Ribavirin for Hepatitis C Patients Concomitant With Hepatocellular Carcinoma Unknown status NCT00834860 Phase 4 peginterferon alpha-2a and ribavirin
7 Nucleoid as an Adjuvant Therapy After Radiofrequency Ablation for Hepatocellular Carcinoma Unknown status NCT00555334 Phase 4 lamivudine or entecavir
8 Radiotherapy as an Adjuvant Therapy After Radiofrequency Ablation for Hepatocellular Carcinoma Unknown status NCT00557024 Phase 4
9 TACE as an Adjuvant Therapy After Radiofrequency Ablation (RFA) for Hepatocellular Carcinoma Unknown status NCT00556803 Phase 4
10 Radiofrequency Ablation Versus Hepatic Resection for the Treatment of Hepatocellular Carcinomas Smaller Than 2 cm Unknown status NCT01351194 Phase 4
11 Hepatic Resection Versus Transcatheter Arterial Chemoembolization for Hepatocellular Carcinoma Complicated by Portal Vein Tumor Thrombosis Unknown status NCT01350206 Phase 4
12 Transcatheter Arterial Chemoembolization Combined With Sorafenib for Unresectable Hepatocellular Carcinoma Unknown status NCT01833299 Phase 4
13 Efficacy of Antiviral Therapy After Radical Resection for Hepatitis B Virus-Related Hepatocellular Carcinoma Unknown status NCT00768157 Phase 4 antiviral treatment (lamivudine or entecavir)
14 Prophylactic Antibiotics Before RFA for HCC Unknown status NCT02534961 Phase 4 Cefazolin
15 Trial of Ablation of Small Hepatocellular Carcinomas in Patients of Cirrhosis Unknown status NCT01438437 Phase 4
16 Primary Prevention of Patients With Hepatocellular Carcinoma and Concomitant Esophageal Varices Unknown status NCT01970748 Phase 4 Propranolol
17 Synergistic Treatment for Hepatocellular Carcinoma (HCC) Using Transcatheter Arterial Chemoembolization (TACE) With Anti-hepatitis B Virus (Anti-HBV) Therapy Unknown status NCT01102335 Phase 4 Telbivudine
18 A RCT of Oral S-1 in Combination With Sequential HAIC of Oxaliplatin After TACE in Patients With Advanced HCC Unknown status NCT01997957 Phase 4 S-1
19 Radiofrequency Ablation Combined With Transcatheter Arterial Chemoembolization Versus Radiofrequency Ablation Alone for Recurrent Hepatocellular Carcinoma Unknown status NCT01415063 Phase 4
20 Radiofrequency Ablation With or With Transcatheter Arterial Embolization for Hepatocellular Carcinoma Unknown status NCT00554905 Phase 4
21 Endoscopic Treatment Alone Versus Combined Propranolol and Endoscopic Treatment of Acute Variceal Hemorrhage in Patients With Hepatocellular Carcinoma Unknown status NCT01451658 Phase 4 propranolol
22 Chemoembolization With or Without Antiviral Therapy for Unresectable HBV-related HCC With Low HBV DNA Replication Unknown status NCT01894269 Phase 4 Lamivudine 100mg once daily; or Entecavir 0.5mg once daily.
23 Thymalfasin Adjuvant Therapy in Hepatitis B Virus (HBV)-Related Hepatocellular Carcinoma (HCC) After Curative Resection Unknown status NCT02281266 Phase 4 thymalfasin;nucleoside analog (suggest to use entecavir)
24 A Clinical Trail of Iodine[131I] Metuximab Injection With CIK Cells for Preventing Hepatocellular Carcinoma Unknown status NCT01758679 Phase 4
25 RFA for Small HCC With No-touch Technique Using Octopus Electrode Unknown status NCT02832882 Phase 4
26 RFA for Small HCC With No-touch Technique and Dual Cooled-Wet Electrode Unknown status NCT02806076 Phase 4
27 A Trial of EVL\GVS Alone vs. EVL\GVS Combined Propranolol Unknown status NCT01298284 Phase 4 propranolol
28 Influence of Antiviral Treatment to the Long-Term Prognosis of Patients With Chronic HBV Infection Unknown status NCT00810524 Phase 4 lamivudine;Telbivudine;Enticavir;Adefovir Dipivoxil Tablets
29 Anesthetic Agents and Acute Kidney Injury After Liver Resection Surgery Unknown status NCT02174575 Phase 4 Sevoflurane;Desflurane
30 Endoscopic Cyanoacrylate Obliteration vs. Nadolol Treatment in the Prevention of Gastric Variceal Rebleeding Unknown status NCT00567216 Phase 4 Nadolol
31 Study to Evaluate the Efficacy of Pravastatin on Survival and Recurrence of Advanced Gastroesophageal Cancer Unknown status NCT01038154 Phase 4 Pravastatin
32 Cholestatic Drug-induced Liver Injury Unknown status NCT01141322 Phase 4 Ursodeoxycholic Acid;Placebo
33 Entecavir for Patients With Decompensated Hepatitis B Virus (HBV)-Related Cirrhosis Unknown status NCT00663182 Phase 4 Entecavir
34 Hepatic Arterial Infusion of Oxaliplatin and Fluorouracil Treatment of Advanced Primary Liver Cancer After TACE Unknown status NCT02557503 Phase 4 Oxaliplatin and fluorouracil
35 Parenteral Fish Oil in Major Laparoscopic Abdominal Surgery Unknown status NCT01819961 Phase 4 MCT/LCT and fish oil;MCT/LCT
36 Intraoperative Intraportal Chemotherapy Combined With Adjuvant Chemotherapy for Stage II and III Colorectal Cancer Unknown status NCT01972503 Phase 4 5-FU and oxaliplatin
37 Cetuximab in Combination With Chemotherapy for the Treatment of Metastatic Colorectal Cancer Unknown status NCT01564810 Phase 4 Cetuximab;chemotherapy of mFOLFOX6 or FOLFIRI
38 Efficacy and Safety of Raltitrexed-based Transarterial Chemoembolisation(TACE)for Colorectal Cancer Liver Metastases Unknown status NCT01959061 Phase 4 Raltitrexed;Oxaliplatin;lipiodol
39 Placebo Controlled Study Using Lovaza as Treatment for Non-Alcoholic Fatty Liver Disease Unknown status NCT00941642 Phase 4 Lovaza;placebo control
40 New Adjuvant Chemotherapy of Non Resectable Liver Metastasis of Colorectal Cancer Without Bleeding, Obstruction Unknown status NCT01307878 Phase 4 chemotherapy ± targeted therapy
41 Relationship Between Platinum Levels in the Blood and Neurotoxicity in Patients Who Are Receiving Oxaliplatin for Gastrointestinal Cancer Unknown status NCT00274885 Phase 4 oxaliplatin
42 Oxaliplatin and Raltitrexed Treatment of Colorectal Cancer With Liver Metastases Unknown status NCT02557490 Phase 4 oxaliplatin and raltitrexed
43 Perioperative Chemotherapy With Herceptin For Potentially Resectable HER-2 Positive Gastric Cancer With Liver Metastasis Unknown status NCT02380131 Phase 4 Oxaliplatin plus Capecitabine;Herceptin
44 Preoperative Chemotherapy With Bevacizumab For Potentially Resectable Gastric Cancer With Liver Metastasis Unknown status NCT01962376 Phase 4 Oxaliplatin;Capecitabine;Oxaliplatin;Capecitabine;Bevacizumab
45 Transhepatic Arterial Chemotherapy (TAC) Versus Transcatheter Arterial Chemoembolization (TACE) Plus Folfox4 as the Treatment of Unresectable Liver Metastasis of Colorectal Cancer Unknown status NCT00868569 Phase 4
46 Xihuang Capsules Prevention of Recurrence in Patients With Hepatocellular Carcinoma After Hepatectomy Recruiting NCT02399033 Phase 4 Xihuang Capsules
47 Magnetic Resonance With Gadoxetic Acid for the Diagnosis of Hepatocellular Carcinoma in Patients With Liver Cirrhosis. Evaluation of Its Impact for the Non-invasive Diagnosis Completed NCT01575574 Phase 4 GADOXETIC ACID
48 Safety and Efficacy of Doxorubicin-eluting-bead Embolization in Patients With Advanced Hepatocellular Carcinoma Active, not recruiting NCT02525380 Phase 4
49 Statin for Preventing Hepatocellular Carcinoma Recurrence After Curative Treatment Recruiting NCT03024684 Phase 4 Atorvastatin;Placebo Oral Tablet
50 Hepatectomy Versus Chemoembolization for Resectable Hepatocellular Carcinoma Beyond Milan Criteria Recruiting NCT02138981 Phase 4

Search NIH Clinical Center for Hepatocellular Carcinoma

Inferred drug relations via UMLS 74 / NDF-RT 52 :


Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Hepatocellular Carcinoma cell therapies at LifeMap Discovery.
Stem-cell-based therapeutic approaches for Hepatocellular Carcinoma:
Tumor infiltrating lymphocytes (TILs) for solid tumors
Embryonic/Adult Cultured Cells Related to Hepatocellular Carcinoma:
Tumor infiltrating lymphocytes PMIDs: 24329789 19342963 23904171 21498393 22996367 19304471 22555974 15800326 23650429 21325070 24218514 8170938 12242449

Cochrane evidence based reviews: liver neoplasms

Genetic Tests for Hepatocellular Carcinoma

Genetic tests related to Hepatocellular Carcinoma:

# Genetic test Affiliating Genes
1 Hepatocellular Carcinoma 30 APC AXIN1 CASP8 CTNNB1 IGF2R MET PDGFRL PIK3CA TP53
2 Neoplasm of the Liver 30

Anatomical Context for Hepatocellular Carcinoma

MalaCards organs/tissues related to Hepatocellular Carcinoma:

42
Liver, T Cells, Lung, Endothelial, Testes, Bone, Colon

Publications for Hepatocellular Carcinoma

Articles related to Hepatocellular Carcinoma:

(show top 50) (show all 20132)
# Title Authors Year
1
Nanocomplexes of Graphene Oxide and Platinum Nanoparticles against Colorectal Cancer Colo205, HT-29, HTC-116, SW480, Liver Cancer HepG2, Human Breast Cancer MCF-7, and Adenocarcinoma LNCaP and Human Cervical Hela B Cell Lines. ( 30893818 )
2019
2
The Diagnostic Value of Arginase-1, FTCD, and MOC-31 Expression in Early Detection of Hepatocellular Carcinoma (HCC) and in Differentiation Between HCC and Metastatic Adenocarcinoma to the Liver. ( 30784016 )
2019
3
A case of hepatocellular carcinoma mimicking hepatic adenoma. ( 30837351 )
2019
4
Impact of preoperative anxiety and depression on quality of life before and after resection of hepatocellular carcinoma. ( 30597297 )
2019
5
Older Age and Disease Duration Are Highly Associated with Hepatocellular Carcinoma in Patients with Autoimmune Hepatitis. ( 30617453 )
2019
6
Development of colorectal cancer predicts increased risk of subsequent hepatocellular carcinoma in patients with alcoholic liver disease: case-control and cohort study. ( 30824851 )
2019
7
Living Donor Liver Transplantation for Hepatocellular Carcinoma: An Asian Perspective. ( 30895483 )
2019
8
Hypomethylation-mediated activation of cancer/testis antigen KK-LC-1 facilitates hepatocellular carcinoma progression through activating the Notch1/Hes1 signalling. ( 30895661 )
2019
9
Update on transarterial approaches to locoregional treatment in hepatocellular carcinoma. ( 30896451 )
2019
10
Comparison of PERCIST and RECIST criteria for evaluation of therapy response after yttrium-90 microsphere therapy in patients with hepatocellular carcinoma and those with metastatic colorectal carcinoma. ( 30896544 )
2019
11
Diagnostic and prognostic value of mRNA expression of phospholipase C β family genes in hepatitis B virus‑associated hepatocellular carcinoma. ( 30896816 )
2019
12
Analysis of Lamin B1, Vimentin and Anti-Ku86 as Prospective Biomarkers of Hepatocellular Carcinoma in Patients with Hepatitis C Virus Infection. ( 30897324 )
2019
13
Lack of galectin-1 exacerbates chronic hepatitis, liver fibrosis, and carcinogenesis in murine hepatocellular carcinoma model. ( 30897344 )
2019
14
Exosomes and Hepatocellular Carcinoma: From Bench to Bedside. ( 30897788 )
2019
15
The coordination between ZNF217 and LSD1 contributes to hepatocellular carcinoma progress and is negatively regulated by miR-101. ( 30898548 )
2019
16
The Use of Checkpoint Inhibitors in Patients With Hepatocellular Carcinoma. ( 30899210 )
2019
17
The anti-tumour effect of Mel and its role in autophagy in human hepatocellular carcinoma cells. ( 30899392 )
2019
18
RAB18 promotes proliferation and metastasis in hepatocellular carcinoma. ( 30899400 )
2019
19
Erratum to "MicroRNA-370 Regulates Cellepithelial-Mesenchymal Transition, Migration, Invasion, and Prognosis of Hepatocellular Carcinoma by Targeting GUCD1" by He Y and He X (Yonsei Med J 2019;60:267-276.). ( 30900430 )
2019
20
Predictors of hepatocellular carcinoma recurrence associated with the use of direct-acting antiviral agent therapy for hepatitis C virus after curative treatment: A prospective multicenter cohort study. ( 30900818 )
2019
21
Focal Nodular Hyperplasia Mimicked Hepatocellular Carcinoma in an Autoimmune Hepatitis Patient With Regression of Cirrhosis. ( 30845888 )
2019
22
Significant Down-regulation of Urea Cycle Generates Clinically Relevant Proteomic Signature in Hepatocellular Carcinoma Patients with Macrovascular Invasion. ( 30901224 )
2019
23
The Delta Subunit of Rod-Specific Photoreceptor cGMP Phosphodiesterase (PDE6D) Contributes to Hepatocellular Carcinoma Progression. ( 30901922 )
2019
24
Pretumor microenvironment of hepatocellular carcinoma: Cancerization or anticancerization? ( 30902783 )
2019
25
Disruption of tumour-associated macrophage trafficking by the osteopontin-induced colony-stimulating factor-1 signalling sensitises hepatocellular carcinoma to anti-PD-L1 blockade. ( 30902885 )
2019
26
Stabilization of E2-EPF UCP protein is implicated in hepatitis B virus-associated hepatocellular carcinoma progression. ( 30903204 )
2019
27
Correction to: Hesperetin induces the apoptosis of hepatocellular carcinoma cells via mitochondrial pathway mediated by the increased intracellular reactive oxygen species, ATP and calcium. ( 30903396 )
2019
28
The fusion landscape of hepatocellular carcinoma. ( 30903738 )
2019
29
Predictive value of intratumour inflammatory cytokine mRNA levels of hepatocellular carcinoma patients and activation of two distinct pathways govern IL-8 induced epithelial-mesenchymal transition in human hepatic cancer cell lines. ( 30903867 )
2019
30
Hepatocellular carcinoma: Clinical-pathological features and HIV infection in Mozambican patients. ( 30903933 )
2019
31
Increased frequency and FOXP3 expression of human CD8+CD25High+ lymphocytes and its relation to CD4 T regulatory cells in patients with hepatocellular carcinoma. ( 30904437 )
2019
32
Upregulated MMP28 in Hepatocellular Carcinoma Promotes Metastasis via Notch3 Signaling and Predicts Unfavorable Prognosis. ( 30906212 )
2019
33
E2F1 transactivates IQGAP3 and promotes proliferation of hepatocellular carcinoma cells through IQGAP3-mediated PKC-alpha activation. ( 30906629 )
2019
34
DSE regulates the malignant characters of hepatocellular carcinoma cells by modulating CCL5/CCR1 axis. ( 30906633 )
2019
35
Landscape of infiltrating B cells and their clinical significance in human hepatocellular carcinoma. ( 30906667 )
2019
36
Novel immunotherapeutic approaches for hepatocellular carcinoma treatment. ( 30907177 )
2019
37
Autophagy-Related 5 Gene rs510432 Polymorphism Is Associated with Hepatocellular Carcinoma in Patients with Chronic Hepatitis B Virus Infection. ( 30907204 )
2019
38
C14orf166 Is a Biomarker for Predicting Hepatocellular Carcinoma Recurrence. ( 30907217 )
2019
39
Outcomes of conventional transarterial chemoembolization for hepatocellular carcinoma ≥10 cm. ( 30907468 )
2019
40
Intra-procedural CT/MR-CEUS Fusion Imaging Improved Thermal Ablation Effect of Hepatocellular Carcinoma: Compared with Conventional Ultrasound. ( 30907477 )
2019
41
Epithelial-mesenchymal transition induced cancer-stem-cell-like characteristics in hepatocellular carcinoma. ( 30908631 )
2019
42
LncRNA CACNA1G-AS1 facilitates hepatocellular carcinoma progression through the miR-2392/C1orf61 pathway. ( 30908634 )
2019
43
A HSD17B13 variant protects from hepatocellular carcinoma development in alcoholic liver disease. ( 30908678 )
2019
44
Improving survival in patients with hepatocellular carcinoma related to chronic hepatitis C and B but not in those related to non-alcoholic steatohepatitis or alcoholic liver disease: a 20-year experience from a national programme. ( 30908822 )
2019
45
Alkannin inhibits proliferation, migration and invasion of hepatocellular carcinoma cells via regulation of miR-92a. ( 30909147 )
2019
46
Combination of Mac-2 Binding Protein Glycosylation Isomer and Up-To-Seven Criteria as a Useful Predictor for Child-Pugh Grade Deterioration after Transarterial Chemoembolization for Hepatocellular Carcinoma. ( 30909405 )
2019
47
Treatment Strategies for Hepatocellular Carcinoma ⁻ a Multidisciplinary Approach. ( 30909504 )
2019
48
Engagement with tNOX (ENOX2) to Inhibit SIRT1 and Activate p53-Dependent and -Independent Apoptotic Pathways by Novel 4,11-Diaminoanthra[2,3-b]furan-5,10-diones in Hepatocellular Carcinoma Cells. ( 30909652 )
2019
49
MCUR1 facilitates epithelial-mesenchymal transition and metastasis via the mitochondrial calcium dependent ROS/Nrf2/Notch pathway in hepatocellular carcinoma. ( 30909929 )
2019
50
Epigenetic Regulation of UDP-Glucuronosyltransferase by microRNA-200a/-183: Implications for Responses to Sorafenib Treatment in Patients with Hepatocellular Carcinoma. ( 30910587 )
2019